From metabolomics to proteomics: understanding the role of dopa decarboxylase in Parkinson’s disease. Scientific commentary on: “Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease”
Authors:
- 18 May 2024
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica
- Vol. 147 (1) , 1-3
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s diseaseActa Neuropathologica, 2024
- Metabolomic profiling reveals altered phenylalanine metabolism in Parkinson’s disease in an Egyptian cohortFrontiers in Molecular Biosciences, 2024
- Targeted metabolomic analysis in Parkinson’s disease brain frontal cortex and putamen with relation to cognitive impairmentnpj Parkinson's Disease, 2023
- Elucidating the Interaction between Pyridoxine 5′-Phosphate Oxidase and Dopa Decarboxylase: Activation of B6-Dependent EnzymeInternational Journal of Molecular Sciences, 2022
- Severe Hyperhomocysteinemia in a Patient with Parkinson DiseaseClinical Chemistry, 2022
- Advances in Proteomic and Metabolomic Profiling of Neurodegenerative DiseasesFrontiers in Neurology, 2022
- Enhancing Aromatic L‐amino Acid Decarboxylase Activity: Implications for L‐DOPA Treatment in Parkinson's DiseaseCNS Neuroscience & Therapeutics, 2008
- Aromaticl-amino acid decarboxylase: A neglected and misunderstood enzymeNeurochemical Research, 1996